We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600085:SSEBeijing TongRenTang Co., Ltd. Class A Analysis

Data as of 2026-05-29 - not real-time

CN¥25.65

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at CNY 25.65, which sits below the 20‑day (CNY 26.61) and 50‑day (CNY 27.57) simple moving averages and well under the 200‑day SMA (CNY 31.97), signaling a bearish technical backdrop. The RSI of 35.9 points to mild oversold conditions, while the MACD line remains beneath its signal line, producing a negative histogram that reinforces downside momentum. Current price hovers just above the calculated support of CNY 24.51 and faces resistance near CNY 28.45, with volume trending higher than its 10‑day average, suggesting active trading interest despite the bearish trend.
Fundamentally, revenue has contracted by 11.6% year‑over‑year, yet the company maintains solid gross (41%) and operating (15.2%) margins, and generates robust free cash flow of CNY 2.18 bn. A strong balance sheet—CNY 11.5 bn cash versus CNY 3.5 bn debt (debt‑to‑equity 16%)—supports a generous dividend yield of 4.02% and a payout ratio of 63.6%, indicating dividend sustainability. The DCF‑derived fair value of CNY 26.82 exceeds the market price, implying the stock is undervalued relative to intrinsic expectations despite a PE of 32.5, which is above the industry average of 27.8.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support but still below major SMAs
  • Bearish MACD and modest oversold RSI
  • Attractive dividend yield cushioning downside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value above market price suggesting upside
  • Strong cash generation and low leverage
  • Low beta indicating limited market‑wide volatility exposure

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustainable dividend supported by cash flow
  • Potential recovery in traditional Chinese medicine demand
  • Resilient balance sheet and modest regulatory exposure

Key Metrics & Analysis

Financial Health

Revenue Growth-11.60%
Profit Margin6.48%
P/E Ratio32.5
ROE6.45%
ROA3.28%
Debt/Equity16.12
P/B Ratio2.5
Op. Cash FlowCN¥2.8B
Free Cash FlowCN¥2.2B
Industry P/E27.8

Technical Analysis

TrendBearish
RSI35.9
SupportCN¥24.51
ResistanceCN¥28.45
MA 20CN¥26.61
MA 50CN¥27.57
MA 200CN¥31.97
MACDBearish
VolumeIncreasing
Fear & Greed Index93.13

Valuation

Fair ValueCN¥26.82
GradeUndervalued
TypeValue
Dividend Yield4.02%

Risk Assessment

Beta0.10
Volatility17.83%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.